NMTC vs. SKIN, INFU, ELMD, BSGM, PROF, STIM, SGHT, KRMD, MBOT, and STSS
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Beauty Health (SKIN), InfuSystem (INFU), Electromed (ELMD), Biosig Technologies (BSGM), Profound Medical (PROF), Neuronetics (STIM), Sight Sciences (SGHT), KORU Medical Systems (KRMD), Microbot Medical (MBOT), and Sharps Technology (STSS). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs. Its Competitors
Beauty Health (NASDAQ:SKIN) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.
In the previous week, Beauty Health had 16 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 19 mentions for Beauty Health and 3 mentions for NeuroOne Medical Technologies. Beauty Health's average media sentiment score of 1.10 beat NeuroOne Medical Technologies' score of 1.06 indicating that Beauty Health is being referred to more favorably in the media.
93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 41.0% of Beauty Health shares are owned by company insiders. Comparatively, 8.9% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Beauty Health currently has a consensus price target of $2.81, suggesting a potential upside of 79.71%. NeuroOne Medical Technologies has a consensus price target of $2.23, suggesting a potential upside of 143.17%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Beauty Health.
Beauty Health has a net margin of -6.13% compared to NeuroOne Medical Technologies' net margin of -55.44%. Beauty Health's return on equity of -32.82% beat NeuroOne Medical Technologies' return on equity.
Beauty Health has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
NeuroOne Medical Technologies has lower revenue, but higher earnings than Beauty Health. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Beauty Health, indicating that it is currently the more affordable of the two stocks.
Summary
Beauty Health beats NeuroOne Medical Technologies on 10 of the 16 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 10/14/2025 by MarketBeat.com Staff
